Key Highlights

  • Shares are down 9.50% in pre-market trading to $52.36, after closing down 0.07% at $58.09 the prior session.
  • Novartis, Ionis's partner on pelacarsen, reported that the Phase 3 Lp(a)HORIZON outcomes trial failed to meet its primary endpoint of reducing cardiovascular events.
  • A separate Novartis trial miss in myotonic dystrophy, also involving an Ionis-licensed asset, has compounded pressure on the stock.
  • The news triggered a wave of analyst price-target cuts, with Canaccord Genuity lowering its target to $85 and HC Wainwright cutting to $100, while both maintain Buy ratings.

Ionis Pharmaceuticals Falls on Partner's Cardiovascular Trial Miss

Ionis Pharmaceuticals (NASDAQ:IONS) shares are down 9.50% in pre-market trading to $52.36, after Novartis (NYSE:NVS), its partner on pelacarsen, an Ionis-developed cardiovascular drug, reported that the Phase 3 Lp(a)HORIZON outcomes trial failed to meet its primary endpoint of reducing cardiovascular events. The disappointing readout, alongside a separate Novartis trial miss in myotonic dystrophy that also involved an Ionis-licensed asset, has triggered a wave of analyst price target cuts as investors reassess the value of Ionis's pipeline and licensing Economics tied to Novartis.

Ionis Pharmaceuticals is a commercial-stage biotechnology company headquartered in Carlsbad, California, and a pioneer in RNA-targeted medicines, leveraging its proprietary antisense oligonucleotide technology platform to treat serious diseases. Founded in 1989 and led by CEO Brett Monia, the company's growing commercial portfolio includes Spinraza for spinal muscular atrophy, Tegsedi and Wainua for hereditary transthyretin-mediated amyloidosis, Waylivra and Tryngolza for familial chylomicronemia syndrome, Qalsody for SOD1-ALS, and Dawnzera for hereditary angioedema, complemented by a robust late-stage pipeline spanning neurology, cardiometabolic, and other high-need disease areas.

Pelacarsen Trial Failure Raises Questions on Licensing Economics

The pelacarsen failure is a significant setback, since the drug was one of the more closely watched cardiovascular Assets in Novartis's late-stage pipeline and represented a key licensing relationship for Ionis. Because pelacarsen was developed by Ionis and licensed to Novartis, the trial's failure to meet its primary endpoint directly affects the milestone payments and Royalty economics Ionis stood to earn had the drug succeeded and reached commercialization. The compounding effect of Novartis's separate myotonic dystrophy trial miss, which also traces back to Ionis-originated antisense technology, has amplified investor concern about the reliability of Novartis's late-stage pipeline more broadly.

Analysts have moved quickly to reflect the changed risk picture, with Canaccord Genuity lowering its price target to $85 and HC Wainwright cutting its target to $100, while both firms maintain Buy ratings on the stock. The maintained bullish ratings suggest analysts still see value in Ionis's broader commercial portfolio and remaining pipeline, even as they reduce the value attributed to the now-failed pelacarsen program.

What This Means for Investors

Today's decline reflects a genuine setback to one of Ionis's more commercially significant partnered programs, though the maintained Buy ratings from covering analysts suggest the failure is being treated as an isolated pipeline disappointment rather than a signal of broader platform risk. Ionis's diversified, already-commercial portfolio across spinal muscular atrophy, amyloidosis, and other rare diseases provides some insulation against the loss of pelacarsen's future economics, since those approved products continue generating Revenue independent of the pelacarsen outcome.

Investors will likely want clarity on how the trial failure affects Ionis's broader relationship and future licensing arrangements with Novartis before fully reassessing the stock's risk profile, particularly given that a separate Novartis myotonic dystrophy trial miss also traced back to Ionis-originated antisense technology. The compounding nature of these two setbacks within the same Partnership raises questions about whether investors should expect further disappointments from other Ionis-Novartis collaborations still in development, or whether the pattern reflects broader challenges in translating antisense mechanisms into successful late-stage cardiovascular and neuromuscular outcomes.